1. Zanchetti A, Hansson L, Menard J, et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study for the HOT Study Group. J Hypertens 2001; 19: 819-25.
2. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of the prospectively designed overviews of randomized trials. Lancet 2000; 356: 1955-64.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
4. ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
5. Секция артериальной гипертонии ВНОК. Профилактика, диагностика и лечение артериальной гипертензии. Россий- ские рекомендации (второй пересмотр). Москва 2005.
6. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998; 317: 705-13.
7. Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888-92.
8. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-9.
9. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20: 2099-110.
10. Wolf G. Molecular mechanisms of angiotensin II in the kidney; emerging role in the progression of renal disease: beyond haemo- dynamics. Nephrol. Dial Transplant 1998; 13: 1131-42.
11. Dzau VJ. Tissue angiotensin and pathobiology of vascular dis- ease. A unifying hypothesis. Hypertension 2001; 37: 1047-52.
12. Bottinger EP, Bitzer M. TGF β signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600-10.
13. Folii F, Saad MJ, Velloso L, et al. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-9.
14. Cottone S, Vadala A, Mangano MT, et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens 2000; 13: 172-6.
15. De Jong PE, Brenner BM. From secondary to primary preven- tion of progressive renal disease: the case for screening for albu- minuria. Kidney Int 2004; 66: 2109-18.
16. Stehouwer CD. Endothelial dysfunction in diabetic nephropa- thy: state of art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004; 19: 778-81.
17. Шестакова М.В., Кочемасова Т.В., Горелышева В.А. и др. Роль молекул адгезии (ICAM-1 и Е-селектин) в развитии диабетических микроангиопатий. Тер архив 2002; 6: 24-7.
18. Шестакова М.В., Ярек-Мартынова И.Р., Иванишина Н.С. и др. Кардиоренальный синдром при сахарном диабете 1 типа: роль дисфункции эндотелия. Кардиология 2005; 6: 35-41.
19. Rosenson RS, Reasner CA. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Curr Opin Cardiol 2004; 19: 480-7. 20. Чазова И.Е., Мычка В.Б. Метаболический синдром. Моск- ва 2004.
20. Gasic S, Wagner OF, Fasching P, et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999;12(2 Pt.1): 217-22.
21. Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002; 105: 457-61.
22. Шестакова М.В. Нефропротекция: роль артериального давления в прогрессировании патологии почек. Зависит ли нефропротективный эффект от выбора антигипертензивного препарата? Тер архив 2001; 6: 64-6.
23. Gertsein HC, Bosch J, Pogue J, et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: the MICRO-HOPE study. Diabetes Care 1996; 19: 1225-8.
24. The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
25. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.
26. Taal MW, Brenner BM. Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens 2002; 11: 377-81.
27. Швецов М.Ю., Медведева Т.Ю., Оконова Е.Б. и др. Блокаторы ангиотензиновых рецепторов 1 типа - новый класс нефропротективных препаратов. Клин фармакол тер 2002; 11(2): 62-9.
28. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
29. McMurray JJV. Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-2 and Val-HeFT? JRAAS 2001; 2: 89-92.
30. Lindholm L, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
31. Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur Heart J 2005; 26(24): 2616-22.
32. Remuzzi G, Schiepatti A, Ruggenenti P. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 2002; 346: 1145-51.
33. Mogensen CE. The kidney in diabetes: how to control renal and related cardiovascular complications. Am J Kidney Dis 2001; 37: S2-6.
34. Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш. и др. Диабетическая нефропатия: факторы риска быстрого прогрессирования почечной недостаточности. Тер архив 1999; 6: 38-41.
35. Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50-5.
36. Strutz F, Bramlage P, Paar WD. Effect of three months’ treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients. Curr Med Res Opin 2005; 21(9): 1433-40.
37. Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004; 20(10): 1625-31.
38. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
39. Keane WF, Kurokawa K, Lyle PA, et al. Treatment of type 2 diabetic patients with AT1-receptors antagonists: lessons from recent trials. Clin Exp Nephrol 2002; 6: 175-81.
40. Opie LH, Parving H-H. Diabetic nephropathy. Can renoprotection be extrapolated to cardiovascular protection? Circulation 2002; 106: 643-5.
41. Persson F, Rossing P, Hovind P, et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55(12): 3550-5.
42. Llewelyn DE, Garcia-Puig J. How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics. J Renin Angiotensin Aldosterone Syst 2004; 5(3): 141-5.
43. Rossing K, Christensen PK, Andersen S, et al. Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. Diabetes Care 2003; 26(3): 569-74.
44. Andersen S, Brochner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003; 26(12): 3296-302.
45. Komajada M. Are angiotensin II receptor blockers indicated in chronic heart failure? Heart 2002; 87: 1-2.
46. Беленков Ю.Н., Мареев В.Ю. Как мы лечим больных с сердечно-сосудистыми заболеваниями в реальной клинической практике. Тер архив 2003; 8: 5-11.
47. Palmer AJ, Rodby RA. Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. Kidney Int Suppl 2004; (92): S118-20.
48. Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27(8): 1897-903.
49. Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается. Тер архив 2005; 9: 5-12.
50. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68(3): 1190-8.
51. Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом. Сons Med 2006; 8(11): 25-30.
52. Lindholm LH, Ibsen H, Borch-Jornsen K, et al. Risk of newonset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-86.
53. Schupp M, Pharm B, Janke J, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-? activity. Circulation 2004; 109: 2054-7.
Послать статью по эл. почте 
